The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the “Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns” organized by the Shanghai Caritas Foundation took place at the Guangzhou Southern Airlines Pearl Airport Hotel. During the conference, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) held a launch event for its new rare disease products, Nitric Oxide for Inhalation (INOmax®) and INOmax DSIR Plus Delivery System.